China’s Xindeyuan Bioengineering is going to invest $250 million in the construction of a blood product plant in Samarkand, Uzbekistan, Podrobno.uz reports referring to the Ministry of Health of the Republic of Uzbekistan.
The plant will be located in the Urgut free economic zone and occupy an area of 15 hectares. This is the first-of-its-kind project in Central Asia, and it will allow meeting the domestic demand in blood products and decreasing imports.
In recent years, the demand for high-quality blood components has increased significantly as the number of organ transplant surgeries is increasing in the country. For example, liver transplantation will require up to 30 litres of plasma. Patients with haematological, oncohematological and other serious diseases should be provided with the necessary blood components and medicines.
In this regard, the Uzbek authorities plan to allocate about 128 billion soums for the development of haematology and transfusiology in the coming years. Currently, most of the medicines and reagents used in this area of medicine are imported. The launch of the new plant will allow improving the situation and meeting the domestic demand for blood products.
